Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2017. Refer to TA481: Immunosuppressive therapy for kidney transplant in adults for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | belatacept (Nulojix®) | ||
| Formulation | 250 mg powder for concentrate for solution for infusion | ||
| Reference number | 430 | ||
| Indication | Prophylaxis of graft rejection in adults receiving a renal transplant, in combination with corticosteroids and a mycophenolic acid |
||
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 1712 | ||
| NMG meeting date | 15/05/2012 | ||
| AWMSG meeting date | 20/06/2012 | ||
| Ratification by Welsh Government | 23/07/2012 | ||
| Date of issue | 27/07/2012 | ||
| Date of last review | 30/08/2016 | ||
| NICE guidance | TA481: Immunosuppressive therapy for kidney transplant in adults |
||